Get the Stockscreener App
36.44
7.18%
2.44
Lb Pharmaceuticals Inc stock is traded at $36.44, with a volume of 503.88K.
It is up +7.18% in the last 24 hours and down -15.33% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$34.00
Open:
$34.54
24h Volume:
503.88K
Relative Volume:
1.20
Market Cap:
$1.18B
Revenue:
Net Income/Loss:
$-38.95M
P/E Ratio:
-24.53
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
+5.29%
1M Performance:
-15.33%
6M Performance:
+25.14%
1Y Performance:
+120.58%
1-Day Range:
$34.50
$37.43
1-Week Range:
$33.88
$38.50
52-Week Range:
$14.32
$50.16
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
36.44 | 1.18B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-26 | Initiated | Canaccord Genuity | Buy |
| Oct-06-26 | Initiated | Guggenheim | Buy |
| Oct-05-26 | Downgrade | Roth Capital | Buy → Neutral |
| Oct-02-26 | Initiated | Needham | Buy |
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Jul-07-26 | Initiated | Wolfe Research | Outperform |
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals Grants Inducement Equity Awards to New Chief Medical Officer and Chief Financial Officer - Quiver Quantitative
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Can LB Pharmaceuticals (NASDAQ:LBRX) Keep Its Fresh Rebound Going Strong? - Kalkine Media
LB Pharmaceuticals (NASDAQ:LBRX) Shares Climb 4.7%Should You Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 5.4% Following Analyst Downgrade - MarketBeat
Needham initiates LB Pharmaceuticals stock with buy rating - Investing.com
Apnimed gives 19 new hires the right to buy 481,300 shares - Stock Titan
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
LBRX: LB Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
LB Pharmaceuticals (Nasdaq:LBRX)Stock Analysis - Simply Wall Street
LB Pharmaceuticals (NasdaqGM:LBRX) Stock Price - Simply Wall Street
LB Pharmaceuticals Inc (LBRX) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
LB Pharmaceuticals Names Dr. Susan Kozauer as Chief Medical Officer with Detailed Compensation Package - Kalkine Media
Form 8K LB Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com India
A doctor who helped develop an FDA-approved psychiatric drug joins LB Pharmaceuticals - Stock Titan
LB Pharmaceuticals (LBRX) CFO reports zero share ownership - Stock Titan
Bank of America Corp DE Has $410,000 Stock Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Names Joseph M. Miller as CFO with $530K Salary and 200,000-Share Stock Option - Kalkine Media
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment - Yahoo Finance
LB Pharmaceuticals to Participate in Upcoming September Investor Events - GlobeNewswire
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - kalkinemedia.com
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.3%Here's What Happened - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Appoints Joseph M. Miller as CFO with $530K Salary and Equity Incentives - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
LB Pharmaceuticals Appoints Joseph Miller as New CFO - TipRanks
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - The Manila Times
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - marketscreener.com
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - Yahoo Finance
LB Pharmaceuticals (LBRX) Edges Lower to $47.14 as Support HoldsShakeout Pattern - siam.in
Four new hires get rights to buy 269,000 Zentalis shares - Stock Titan
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Forecast for LBRX Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High After Analyst Upgrade - MarketBeat
H.C. Wainwright raises LB Pharmaceuticals price target to $60 By Investing.com - Investing.com India
H.C. Wainwright raises LB Pharmaceuticals price target to $60 By Investing.com - Investing.com Canada
HC Wainwright Forecasts Strong Price Appreciation for LB Pharmaceuticals (NASDAQ:LBRX) Stock - MarketBeat
Great Lakes Advisors LLC Purchases Shares of 30,410 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighTime to Buy? - MarketBeat
LB (LBRX) Technical Check: Climbs 1.88% to $47.10 on the Day; Level Position: the $44.74 to $49.46 Range Remains in FocusPositive Gamma - vinanet.vn
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - marketbeat.com
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com Nigeria
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com Canada
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com India
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):